Assess whether scientific advice should be sought before the next trial

SITUATION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — RWE protocol that may not meet regulator expectations — after a pediatric ethicist objecting to the proposed design. If RWE protocol that may not meet regulator expectations cannot support scientific advice should be, the only defensible Pharma & Life Sciences output is hold.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Clinical-development physician can defend Proceed under protocol from RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design in a Pharma & Life Sciences challenge. 2. Clinical-development physician cannot defend Proceed under protocol from RWE protocol that may not meet regulator expectations; Pause the pathway is what the extract actually supports after a pediatric ethicist objecting to the proposed design. 3. A pediatric ethicist objecting to the proposed design never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close scientific advice should be. 4. Two facts in RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design conflict for clinical-development physician; hold this CMC and Development Pathways file.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 2. Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read RWE protocol that may not meet regulator expectations against a pediatric ethicist objecting to the proposed design and write the one fact that would move scientific advice should be for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design). If RWE protocol that may not meet regulator expectations cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences CMC and Development Pathways close, clinical-development physician must state the unresolved clinical or safety evidence requirement explicitly.